Close Menu
Invest Intellect
    Facebook X (Twitter) Instagram
    Invest Intellect
    Facebook X (Twitter) Instagram Pinterest
    • Home
    • Commodities
    • Cryptocurrency
    • Fintech
    • Investments
    • Precious Metal
    • Property
    • Stock Market
    Invest Intellect
    Home»Stock Market»This Dividend Stock Is Down 30% in 2025. Should You Buy the Dip or Stay Far, Far Away?
    Stock Market

    This Dividend Stock Is Down 30% in 2025. Should You Buy the Dip or Stay Far, Far Away?

    September 8, 20254 Mins Read


    Constellation Brands (STZ) is a leading international producer and marketer of beer, wine, and spirits. Renowned for its premium portfolio, the company owns iconic brand names such as Corona, Modelo, Robert Mondavi Winery, and Casa Noble Tequila. As one of the fastest-growing consumer packaged goods companies in the U.S., Constellation focuses on innovation, premiumization, and strong engagement with evolving consumer tastes.

    So far this year, however, STZ stock is down. Should investors consider buying shares of this legacy name on the dip? Let’s take a closer look.

    Constellation Brands stock has experienced a steep decline of late, falling about 8% in the last five days, 13% over the last one month, and 20% in the past six months. Year-to-date (YTD), STZ stock has retreated roughly 33%, while its 52-week performance shows a 40% loss, currently trading near its yearly low.

    In stark contrast, the S&P 500 ($SPX) has posted double-digit gains in 2025, driven by the strength of the tech sector and positive market sentiment. This divergence highlights underperformance by STZ stock relative to the broader index, indicating investor caution around the company despite generally bullish conditions in the equity market.

    www.barchart.com
    www.barchart.com

    Constellation Brands finished its first quarter of fiscal 2025 with EPS of $3.22 and total revenue reaching $2.52 billion, coming in below analyst expectations for EPS of $3.31 and $2.55 billion in revenue. Both results also declined compared to the same period last year, indicating sustained headwinds for its beer, wine, and spirits lines.

    Breaking apart segment performance, beer net sales declined 1.7% to $2.23 billion, falling short of projected figures, while wine and spirits showed a sharper 28% drop to $280.5 million. Operating income from beer came in at $873.4 million, also below consensus estimates, while losses continued for wine and spirits.

    That said, the company’s free cash flow remained strong at $444 million, alongside $637 million of operating cash flow and stable net leverage of 3.0X. In Q1, Constellation Brands repurchased $306 million in shares and issued $182 million in dividends.

    STZ stock declined following a downward revision of the company’s fiscal 2026 financial outlook, driven by weaker consumer demand. The company lowered its EPS forecast to a range of $10.77 to $11.07 from an earlier estimate of $12.07 to $12.37. Meanwhile, comparable EPS was adjusted to $11.30 to $11.60, down from $12.60 to $12.90. This contrasts with the consensus EPS estimate of $12.65 for the fiscal year.

    The updated guidance also reflects a new expectation for enterprise organic net sales growth to fall between a decline of 6% and growth of 4%. That’s compared to the prior outlook of a 2% decline to 1% growth. For the beer segment specifically, net sales are now anticipated to decrease by 4% to 2%, reversing earlier projections anticipating as much as 3% growth.

    CEO Bill Newlands attributed the revisions to ongoing macroeconomic challenges that have suppressed consumer spending and increased purchasing volatility. CFO Garth Hankinson also pointed to distributor-level inventory rebalancing as a sign of softer consumer trends, projecting shipment volumes to lag depletion rates in Q2.

    Despite the present downward market sentiment, STZ stock has a fairly positive view among Wall Street experts with a consensus “Moderate Buy” rating and a mean price target of $181.43, reflecting potential upside of 25% from current levels. Out of the 23 analysts with coverage, 10 analysts give STZ stock a “Strong Buy” rating, three provide a “Moderate Buy” rating, eight have a “Hold,” one analyst has a “Moderate Sell,” and one analyst has a “Strong Sell” rating.

    www.barchart.com
    www.barchart.com

    On the date of publication, Ruchi Gupta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Stock Market LIVE Updates: Sensex, Nifty flat at pre-open; Bharti Airtel, NCC, SMS Pharma, Zydus Life in focus

    Stock Market

    BBC Learning English – The Reading Room / Can we trust technology in sport?

    Stock Market

    Yields above 5%! Here are my 2 favourite FTSE 100 dividend stocks

    Stock Market

    Nifty 50 crosses 26,000 intra-day, but last-hour fall drags index below 25,900

    Stock Market

    Big tech, states and utilities weigh in on DOE data center plan

    Stock Market

    Want Over $7,000 in Annual Dividends? Invest $25,000 in Each of These 4 Stocks.

    Stock Market
    Leave A Reply Cancel Reply

    Top Picks
    Fintech

    Chiba Bank launches personalized features and insights powered by Moneythor | by Norbert Gehrke | Tokyo FinTech | Oct, 2024

    Investments

    Reeves must avoid awakening the bond market bear

    Commodities

    Call for emergency plan to restore agricultural plantations devastated by Melissa in the South

    Editors Picks

    India, Oman to sign CEPA trade pact very soon: Oman’s Ambassador to India

    September 20, 2025

    Ghana assures diaspora: Your investments are safe, thriving and protected

    September 17, 2025

    Woodside Energy dépose une plainte contre le Sénégal auprès du CIRDI

    June 2, 2025

    HBM Healthcare Investments envisagerait de vendre son activité pharmaceutique Swixx -Le 21 février 2025 à 05:35

    February 20, 2025
    What's Hot

    Le PDG d’Elyse Energy : « C’est un sacré défi de mobiliser 2 milliards de capitaux »

    February 19, 2025

    Almost 500,000 homeowners fail to meet extended local property tax deadline – The Irish Times

    November 12, 2025

    Phoenix Copper lève 500 000 £ grâce à un placement

    June 12, 2025
    Our Picks

    La Banque agricole de Chine rachète 40 milliards de yuans d’obligations de catégorie 2

    May 7, 2025

    Novak Djokovic’s retirement date predicted by Serena Williams’ ex-coach – ‘It’s perfect’

    September 11, 2025

    Succès de l’Augmentation de Capital de Haffner Energy par émission d’ABSA avec maintien du DPS pour un montant de 7 M€

    April 1, 2025
    Weekly Top

    Stock Market LIVE Updates: Sensex, Nifty flat at pre-open; Bharti Airtel, NCC, SMS Pharma, Zydus Life in focus

    November 25, 2025

    Brookfield builds decarbonisation platform in South-east Asia

    November 25, 2025

    Donald Trump says China’s Xi ‘pretty much’ agreed to expand agricultural buys

    November 25, 2025
    Editor's Pick

    Global Fintech Investment Falls to $51.9 Billion, but Deal Volume Offers Optimism, Says KPMG’s Pulse of Fintech

    August 5, 2024

    RBI adds 25 tonne of gold in second half of FY25

    May 5, 2025

    Pharmaceutical companies announce major investments in Mexico

    August 7, 2025
    © 2025 Invest Intellect
    • Contact us
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.